UBS Remains Sidelined on Polaris Industries (PII) Following Updated guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/26/2026
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
- Stock action shows confidence in central banks: BofA’s Hartnett
- Oil prices slide about 2% as US, Iran explore path out of war
- Why stocks held up despite rising yields and $100 oil? These 2 words explain it
- Barclays asks if equity markets are nearing the boiling point
- White House blocks CNN from Air Force One trip, Washington Post reports
- Merck and Daiichi Sankyo withdraw lung cancer drug application
- Exclusive-SK Hynix's Solidigm weighs IPO that could value the unit at up to $150 billion, sources say
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
- Fox Factory sells Marucci Sports for $225M, cuts debt
Wedbush Cuts Price Target on Polaris Industries (PII) Following guidance Cut
September 13, 2016 7:28 AM EDTWedbush maintained a Neutral rating on Polaris Industries (NYSE: PII), and cut the price target to $77.00 (from $88.00), following the company's guidance cut. Polaris announced on Monday, a cut to 2016 guidance, from $6.00-$6.30 to $3.30-$3.80. The starting point for 2017 earnings estimates is now $4.50-$5.00 vs. the... More
Polaris (PII) call put ratio; 1 call for 22 puts after cutting guidance
September 12, 2016 12:30 PM EDTPolaris Industries (NYSE: PII) September and October 70 puts are active on total call volume of 6,400 contracts (280 calls) after the company cut its full year guidance amid several vehicle recalls that have delayed sales. September put option implied volatility is at 48, October is at 43; compared to its 52-week range of 29 to 51.
... MorePre-Open Stock Movers 09/12: (RPTP) (CLSN) (PRGO) Higher; (GERN) (AMRN) (PII) Lower (more...)
September 12, 2016 9:23 AM EDTGeron Corporation (Nasdaq: GERN) 27.6% LOWER; today provided updates on the clinical trials being conducted by Janssen Research & Development, LLC, of the telomerase inhibitor imetelstat. Planned internal reviews of initial data from both trials have been completed by Janssen, and both trials are continuing in order to evaluate additional and more mature data.
Neuralstem, Inc. (Nasdaq: CUR) 21.6% HIGHER; announced that on September 7, 2016, it entered into definitive agreements with Tianjin Pharmaceutical Holding Group for the private placement of common... More
Harley-Davidson (HOG) on Watch After Polaris (PII) Cuts FY Forecast
September 12, 2016 9:04 AM EDT(Updated)
Harley-Davidson (NYSE: HOG) was in focus Monday after peer Polaris (NYSE: PII) sharply lowered its FY EPS forecast.
... MorePolaris Industries (PII) Cuts FY16 EPS Outlook
September 12, 2016 9:03 AM EDTPolaris Industries Inc. (NYSE: PII) provided an update to its full-year guidance. The Company now expects full-year 2016 earnings to be in the range of $3.30 to $3.80 per diluted share, $2.50 to $2.70 per diluted share lower than previously expected of which approximately two-thirds is expected to be incurred in the third quarter. Polaris also expects total Company sales for the full-year 2016 to be down in the mid to high-single digit percent range compared to previously issued guidance of flat to down two percent.
*** The Street sees FY16 EPS of $6.01.
Since Polaris last updated... More
